Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3
1(33.3%)
Early Phase 1
1(33.3%)
Phase 2
1(33.3%)
3Total
Phase 3(1)
Early Phase 1(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01490086Phase 2Completed

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Role: lead

NCT05184335Phase 3Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Role: lead

NCT02932852Early Phase 1Unknown

Autologous Adipose-Derived Adult Stem Cell Transplantation for Corneal Diseases

Role: collaborator

All 3 trials loaded